Presentationer och intervjuer

 PresentationMediaDate
AlzeCure medverkar på Erik Penser Banks temadag Life Science den 2 december, 2021 2 december, 2021
Follow us - Stay updated 22 november, 2021
AlzeCure Pharma - Redeye Life Science Day 11 november, 2021
AlzeCure update on the latest developments - Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans. 22 oktober, 2021
Alzecure presents at Healthcare Innovation Summit 7 oktober, 2021
Characterization of positive allosteric modulators of TrkB for the treatment of depression 2 oktober, 2021
Alzecure Pharma - Naventus Life Science Summit 29 september, 2021
Aktiespararna intervjuar VD Martin Jönsson - senaste kvartalsrapporten och framtidsutsikterna 20 september, 2021
AlzeCure Pharma – Aktiedagen Stockholm 7 september, 2021
Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer 1 september, 2021
NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research 1 september, 2021
Company Overview & Vision by Martin Jönsson CEO 1 september, 2021
Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD 1 september, 2021
Strategy Update on Alzheimer’s Disease & NeuroRestore 1 september, 2021
ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021 29 juli, 2021
Negativa allosteriska modulatorer av TrkA för behandling av smärta - Vetenskaplig presentation på smärtkonferensen IASP, juni 2021 11 juni, 2021
Om att drabbas av Alzheimers sjukdom, diagnostik, vården idag samt framtida behov - med Bengt Winblad, professor, senior vid Karolinska Institutet. 11 juni, 2021
Om Alzstatin och läkemedel vid Alzheimers sjukdom - med Bengt Winblad, professor, senior vid Karolinska Institutet. 11 juni, 2021
Om AlzeCures uppkomst och utveckling - Ett embryo som kan bli något stort - med Bengt Winblad, professor, senior vid Karolinska Institutet. 11 juni, 2021
ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain - Vetenskaplig presentation på smärtkonferensen IASP, juni 2021 9 juni, 2021
Alzecure: VD Martin Jönsson presenterar på Redeye Growth Day 7 juni, 2021
CEO Martin Jönsson after the company's annual meeting 17 maj, 2021
Update on Progress in the Painless Platform, May 11, 2021 11 maj, 2021
Company overview and goals by CEO Martin Jönsson, 11 Maj, 2021 11 maj, 2021
Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, 11 Maj, 2021 11 maj, 2021
ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, 11 Maj, 2021 11 maj, 2021
TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, 11 Maj, 2021 11 maj, 2021
Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video) 20 april, 2021
Analysguiden: "Smärtprojekt, en dold diamant” 10 mars, 2021
Alzecure: Intervju med vd Martin Jönsson (video) 1 mars, 2021
Analysguiden: Intervju med AlzeCure Pharma "Vi har tagit stora kliv under 2020" 8 februari, 2021
VD Martin Jönsson presentation, Aktiedagen Lund 27 januari, 2021
Intervju med Johan Sandin (CSO) i Aktiespararnas analysguide 22 januari, 2021
Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies 14 januari, 2021